Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astex Signs with Novartis

December 12, 2005 | A version of this story appeared in Volume 83, Issue 50

Astex Therapeutics has granted a worldwide license to Novartis for its cell-cycle inhibitor, AT9311, with an option to license a second inhibitor, AT7519, currently in Phase I trials. Both are small molecules that treat cancer. Astex will receive an up-front payment and deferred equity payments of $25 million, with a potential for up to $520 million in fees and equity payments, option payments, and milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.